Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Total Current Liabilities (2020 - 2026)

Invivyd's (IVVD) quarterly Total Current Liabilities came in at $31.0 million in Q2 2026, down 30.2% on a YoY basis from $44.5 million in Q2 2025, and down 9.18% quarter-over-quarter from $34.2 million in Q4 2025.

Analysis

Invivyd (IVVD) Total Current Liabilities (2020 - 2026) Analysis & Trends

Invivyd (IVVD) has reported Total Current Liabilities for 7 consecutive years, with $31.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Total Current Liabilities fell 30.2% year-over-year to $31.0 million; the trailing twelve-month figure through Jun 2026 stood at $31.0 million (down 30.2% YoY), and the FY2025 full-year result was $34.2 million, down 44.88% from the prior year.
  • Total Current Liabilities eased to $31.0 million in Q2 2026 per IVVD's latest filing, from $34.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $95.5 million in Q1 2022 and bottomed at $22.1 million in Q1 2023.
  • Historically, Total Current Liabilities has averaged $46.1 million across 5 years, with a median of $44.5 million in 2025.
  • The sharpest annual moves came in 2023 and 2024: Total Current Liabilities plunged 76.91% in 2023, then jumped 193.17% in 2024.
  • Over 5 years, Total Current Liabilities stood at $25.0 million in 2022, then soared by 100.91% to $50.3 million in 2023, then gained by 23.23% to $62.0 million in 2024, then sank by 44.88% to $34.2 million in 2025, then declined by 9.18% to $31.0 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods registered $31.0 million, $34.2 million, and $44.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 25.50 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 11.02 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 3.94 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 5.53 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 1.58 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 2.53 Bn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 1.51 Bn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 3.92 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 438.74 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn 31.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 31.03 Mn
Dec 31, 2025 34.16 Mn
Sep 30, 2025 44.50 Mn
Jun 30, 2025 44.45 Mn
Mar 31, 2025 49.60 Mn
Dec 31, 2024 61.98 Mn
Sep 30, 2024 78.54 Mn
Jun 30, 2024 36.70 Mn
Mar 31, 2024 36.35 Mn
Dec 31, 2023 50.29 Mn
Sep 30, 2023 26.79 Mn
Jun 30, 2023 32.51 Mn
Mar 31, 2023 22.06 Mn
Dec 31, 2022 25.03 Mn
Sep 30, 2022 46.13 Mn
Jun 30, 2022 67.88 Mn
Mar 31, 2022 95.53 Mn
Dec 31, 2021 62.06 Mn
Sep 30, 2021 53.05 Mn
Jun 30, 2021 37.90 Mn